Flibanserin Ineffective for Hypoactive Sexual Desire Disorder in Women
Am Fam Physician. 2016 Sep 1;94(5):384a-386.
Is flibanserin (Addyi) a safe and effective treatment of hypoactive sexual desire disorder in premenopausal women?
Flibanserin produces a minimal effect on sexual desire and minimally increases the number of satisfying sexual events in women (less than one-half an event per month increase). Many women will be unable to tolerate the adverse effects. (Level of Evidence = 1a)
To assemble studies for inclusion, these authors searched three trial registries and 13 electronic databases, including the Cochrane Library, with reference lists of retrieved articles to identify randomized studies. They included studies published
POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, Associate Deputy Editor.
A collection of POEMs published in AFP is available at http://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions